TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study

被引：0
|
作者：
Angevin, E.
Lopez, J. A.
Pande, A.
Moldovan, C.
Shi, M.
Soria, J. C.
Wang, X.
Harzstark, A.
Saro, J.
Escudier, B.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Novartis Oncol, E Hanover, NJ USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3563
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC)
    Brick, A. J.
    McDermott, D. F.
    Clement, J. M.
    Kwabi, C.
    Shah, K.
    Weiner, J. R.
    Duh, M. S.
    Neary, M. P.
    Oh, W. K.
    Choueiri, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
    Rini, Brian I.
    George, Daniel J.
    Michaelson, M. Dror
    Rosenberg, Jonathan E.
    Bukowski, Ronald M.
    Sosman, Jeffrey A.
    Stadler, Walter M.
    Margolin, Kim
    Hutson, Thomas E.
    Baum, Charles M.
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [45] Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).
    Hahn, Andrew W.
    Alhalabi, Omar
    Meric-Bernstam, Funda
    Naing, Aung
    Jonasch, Eric
    Msaouel, Pavlos
    Piha-Paul, Sarina Anne
    Hong, David S.
    Pant, Shubham
    Yap, Timonthy A.
    Campbell, Erick
    Le, Hung
    Tannir, Nizar M.
    Roszik, Jason
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [47] Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC).
    Marsh, L.
    Khan, M.
    Needle, M.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [48] Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard
    Barthelemy, Philippe
    Ravaud, Alain
    Negrier, Sylvie
    Needle, Michael N.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] ORAL THALIDOMIDE IN PROGRESSING METASTATIC RENAL CELL CARCINOMA (MRCC): A PROSPECTIVE PHASE II STUDY
    Caserta, Claudia
    Bracarda, Sergio
    Ludovini, Vienna
    Darwish, Samir
    Pistola, Lorenza
    Tofanetti, Francesca M.
    Marrocolo, Francesca
    Tonato, Maurizio
    ANNALS OF ONCOLOGY, 2004, 15 : 91 - 92
  • [50] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
12345